Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NVP-BAW2881 (BAW2881) 是一种选择性的 VEGFR2抑制剂,其 IC50=9 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 282 | 现货 | ||
2 mg | ¥ 398 | 现货 | ||
5 mg | ¥ 661 | 现货 | ||
10 mg | ¥ 1,160 | 现货 | ||
25 mg | ¥ 2,230 | 现货 | ||
50 mg | ¥ 3,660 | 现货 | ||
100 mg | ¥ 5,290 | 现货 | ||
500 mg | ¥ 10,800 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 617 | 现货 |
产品描述 | NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation. |
靶点活性 | VEGFR2 (human):9 nM, B-Raf (V599E):76 nM, VEGF2 (mouse):165 nM, c-ABL:99 nM, C-Raf1:24 nM |
体外活性 | 局部施用NVP-BAW2881在小鼠和家猪皮肤中,能减少VEGF-A诱导的血管通透性.NVP-BAW2881能够靶向鼠源、猪源和人源VEGFR2的酪氨酸激酶区域.NVP-BAW2881减少小鼠的皮肤损伤处白细胞浸润,减少表皮增生、正常表皮角化细胞分化以及显示较少的血管异常.NVP-BAW2881处理过的小鼠的血管变小、数量减少.相较于对照组,实验组小鼠的耳肿胀、皮肤炎症、淋巴结肿大、皮肤红斑得到改善.虽然两种给药途径都有效(口服和局部施用),但全身性用药比局部给药更为强效. |
体内活性 | 体外实验证明NVP-BAW2881能够抑制人淋巴管内皮细胞和脐静脉内皮细胞的增殖、迁移以及小管生成。 |
细胞实验 | HUVECs or LECs (1.2×103) were seeded into fibronectin-coated 96-well plates. After 24 hours, the cells were transferred into LEC medium containing 2% fetal bovine serum and incubated for an additional 24 hours. Cells(eight wells/condition) were incubated with medium alone(control), 20 ng/ml VEGF-A, or a combination of 20 ng/ml VEGF-A and 1 nmol/L to 1 mol/L NVP-BAW2881. Proliferation was also assayed in LECs incubated with 500 ng/ml VEGF-C. The dimethyl sulfoxide concentration was adjusted to 0.1% in all wells. After 72 hours, cells were incubated with 5-methylumbelliferylheptanoate for subsequent fluorescent quantification of viable cells, using a SpectraMax Gemini electron microscope. (Only for Reference) |
别名 | BAW2881 |
分子量 | 424.38 |
分子式 | C22H15F3N4O2 |
CAS No. | 861875-60-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 78 mg/mL (183.8 mM)
Ethanol: 16 mg/mL (37.7 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.3564 mL | 11.7819 mL | 23.5638 mL | 58.9095 mL |
5 mM | 0.4713 mL | 2.3564 mL | 4.7128 mL | 11.7819 mL | |
10 mM | 0.2356 mL | 1.1782 mL | 2.3564 mL | 5.8909 mL | |
20 mM | 0.1178 mL | 0.5891 mL | 1.1782 mL | 2.9455 mL | |
DMSO | 50 mM | 0.0471 mL | 0.2356 mL | 0.4713 mL | 1.1782 mL |
100 mM | 0.0236 mL | 0.1178 mL | 0.2356 mL | 0.5891 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NVP-BAW2881 861875-60-7 Angiogenesis Cytoskeletal Signaling MAPK Tyrosine Kinase/Adaptors VEGFR Raf Bcr-Abl NVP-BAW-2881 NVPBAW2881 inhibit NVP BAW2881 Vascular endothelial growth factor receptor Inhibitor BAW 2881 BAW2881 NVP-BAW 2881 BAW-2881 inhibitor